GlobalData on MSN

Denali makes $275m funding agreement with Royalty Pharma

Denali has entered a $275m royalty funding agreement with Royalty Pharma based on future net sales of tividenofusp alfa ...
Fierce Biotech

Royalty pens $275M financing deal for Denali drug awaiting delayed FDA decision

In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...

California boy, 3, receives first-ever gene therapy for his rare disease: ‘It’s just so exciting’

A California toddler is the first person in the world to receive gene therapy to treat his devastating disease.
Daily Jang

Hunter syndrome breakthrough: Three-year-old treated with world-first gene therapy

A medical breakthrough is giving new hope to families worldwide, as a three-year-old boy becomes first ever patient with ...

Denali Therapeutics, Royalty Pharma Enter $275 Million Royalty Funding Agreement for Hunter Syndrome Treatment

Denali Therapeutics and Royalty Pharma entered a $275 million royalty funding agreement based on future sales of tividenofusp alfa.

Child with Hunter Syndrome amazes doctors in world-first gene therapy trial

A child with Hunter Syndrome has amazed doctors with his progress after becoming the first person in the world to receive a ...

Denali Enters Into a $275M Funding Deal With Royalty Pharma

DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.
The Citizen

Zach’s Hunter Syndrome case back in court as Medihelp challenges orders

Three years after the first ruling, the medical aid’s reconsideration bid thrusts the ongoing treatment dispute before the ...
Technology Networks

Three-Year-Old Patient With Hunter Syndrome Responds Well to Gene Therapy

Three-year-old Ollie Chu, born with the rare and life-limiting Hunter syndrome, is showing improvement after receiving an ...
Smithsonian Magazine on MSN

This Toddler Was the First Person to Receive a Test Treatment for a Rare Genetic Disorder. Nine Months Later, His Progress Is Inspiring Hope

Oliver Chu is one of five kids participating in a clinical trial investigating a gene therapy for Hunter syndrome, a disorder with symptoms akin to childhood dementia that limits life expectancy ...

3-Year-Old Boy with Rare Condition Amazes Doctors by Becoming World's First Gene Therapy Patient

Oliver Chu was born with a rare genetic condition called Hunter syndrome that impacts physical and mental development. The ...

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

Detailed price information for Royalty Pharma Plc Cl A (RPRX-Q) from The Globe and Mail including charting and trades.